AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cottagnoud, P.
Right arrow Articles by Täuber, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cottagnoud, P.
Right arrow Articles by Täuber, M. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2000, p. 2179-2181, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Synergy between Trovafloxacin and Ceftriaxone against Penicillin-Resistant Pneumococci in the Rabbit Meningitis Model and In Vitro

Philippe Cottagnoud,1,* Fernando Acosta,2 Marianne Cottagnoud,2 Klaus Neftel,2 and Martin G. Täuber3

Department of Internal Medicine, Inselspital,1 Department of Internal Medicine, Zieglerspital,2 and Institute of Medical Microbiology, University of Bern,3 Bern, Switzerland

Received 27 October 1999/Returned for modification 6 March 2000/Accepted 8 May 2000

The bactericidal activities of monotherapy with trovafloxacin (-0.37 ± 0.15 Delta log10 CFU/ml · h), vancomycin (-0.32 ± 0.12 Delta log10 CFU/ml · h), and ceftriaxone (-0.36 ± 0.19 Delta log10 CFU/ml · h) for the treatment of experimental meningitis in rabbits due to a clinical penicillin-resistant pneumococcal strain (MIC, 4 mg/liter) were similar. The combination of ceftriaxone with trovafloxacin considerably improved the killing rates (-0.67 ± 0.16 Delta log10 CFU/ml · h) and was slightly superior to ceftriaxone with vancomycin (killing rate, -0.53 ± 0.22 Delta log10 CFU/ml · h), the regimen most commonly used in clinical practice. In vitro, synergy was demonstrated between ceftriaxone and trovafloxacin by the checkerboard method (fractional inhibitory concentration index, 0.5) and by time-killing assays over 8 h.

* Corresponding author. Mailing address: Department of Internal Medicine, Inselspital, 3010 Bern, Switzerland. Phone: 41316322111. Fax: 41316323847. E-mail: pcottagn{at}insel.ch.

Antimicrobial Agents and Chemotherapy, August 2000, p. 2179-2181, Vol. 44, No. 8
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.